173 related articles for article (PubMed ID: 31106203)
1. The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs.
Cook N; Geier A; Schmid A; Hirschfield G; Kautz A; Schattenberg JM; Balp MM
Front Med (Lausanne); 2019; 6():61. PubMed ID: 31106203
[No Abstract] [Full Text] [Related]
2. Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis.
Cook N; Geier A; Schmid A; Hirschfield G; Kautz A; Schattenberg JM; Balp MM
JHEP Rep; 2020 Apr; 2(2):100081. PubMed ID: 32190823
[TBL] [Abstract][Full Text] [Related]
3. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
4. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
[TBL] [Abstract][Full Text] [Related]
5. Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.
Cook NS; Nagar SH; Jain A; Balp MM; Mayländer M; Weiss O; Chatterjee S
Adv Ther; 2019 Feb; 36(2):478-491. PubMed ID: 30547371
[TBL] [Abstract][Full Text] [Related]
6. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
11. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
[TBL] [Abstract][Full Text] [Related]
12. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.
Zachou K; Azariadis K; Lytvyak E; Snijders RJALM; Takahashi A; Gatselis NK; Robles M; Andrade RJ; Schramm C; Lohse AW; Tanaka A; Drenth JPH; Montano-Loza AJ; Dalekos GN;
JHEP Rep; 2023 Aug; 5(8):100778. PubMed ID: 37456672
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
[TBL] [Abstract][Full Text] [Related]
14. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
15. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
Younossi ZM; Stepanova M; Nader F; Loomba R; Anstee QM; Ratziu V; Harrison S; Sanyal AJ; Schattenberg JM; Barritt AS; Noureddin M; Bonacci M; Cawkwell G; Wong B; Rinella M;
Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2050-2058.e12. PubMed ID: 34274514
[TBL] [Abstract][Full Text] [Related]
17. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
18. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review.
Grønkjær LL; Lauridsen MM
JHEP Rep; 2021 Dec; 3(6):100370. PubMed ID: 34805816
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
